Zepbound®: tirzepatide for weight and sleep apnea, and what it costs

Zepbound® is Eli Lilly’s FDA-approved tirzepatide, a weekly injection that acts on two gut-hormone receptors, GIP and GLP-1. It is approved for chronic weight management in adults and for moderate to severe obstructive sleep apnea in adults with obesity. Through VevaMD a board-certified physician decides whether it fits you; you pay a VevaMD membership, and Eli Lilly directly for the medication.

FDA-approved brandWeekly prefilled pen

See if Zepbound fits me →

A board-certified, US-licensed physician reviews every intake.

What Zepbound costs at VevaMD

  • VevaMD membership: $149 a month, or $237 every 3 months ($79/mo. Save $210 versus paying monthly.). Two charges. This price is the VevaMD membership for physician review. You pay the manufacturer directly for the medication.
  • Zepbound KwikPen: $299 a month at 2.5 mg, $399 a month at 5 mg, and $449 a month from 7.5 mg through 15 mg when you refill within 45 days of the last delivery. Lilly lists a higher regular price if that refill is later, paid to Eli Lilly. In total $448–$598 a month ($149 membership + $299–$449/mo to Eli Lilly).
  • After a physician prescribes, create your LillyDirect account and pay the pharmacy there. VevaMD does not create that account. The published self-pay price applies when they fill it under their terms.
  • Full refund of your first membership payment if nothing is prescribed. The membership does not change with your dose.

What Zepbound is

Zepbound® is tirzepatide, made by Eli Lilly: one molecule that activates the receptors for GIP and GLP-1, two hormones released from the gut after a meal [1]. It is FDA-approved, with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight and a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity [1].

The sleep apnea approval, in December 2024, made it the first medicine approved for that condition in some patients; the FDA linked the improvement in breathing to the weight it helps people lose [2]. Mounjaro® is the same ingredient from Lilly, approved for type 2 diabetes rather than weight.

How Zepbound works

GLP-1 regulates appetite and calorie intake. Zepbound® also activates the receptor for GIP, which studies outside people suggest may add to the effect on food intake, and receptors for both sit in the brain’s appetite centers. According to the label, it lowers calorie intake, the weight it lowers is more fat than lean mass, and it slows stomach emptying, most after the first dose [1]. NIDDK is clear that medicines like it work with healthier eating and more activity, not in place of them [3].

The pen

  • KwikPen®: each pen holds 4 weekly doses, one month of treatment. It is for one person only and is never shared, even with a new needle [1].
  • Where and when: under the skin of the stomach or thigh, or the back of the upper arm if someone else injects it, at any time of day, with or without food, rotating the site each week [1].
  • Price: the VevaMD membership stays the same at every strength; Eli Lilly sets the self-pay price for each strength.

How you get Zepbound through VevaMD

Zepbound through VevaMD is two separate payments. The VevaMD membership, $149/mo or less when you prepay three months, pays for your board-certified physician, the prescription and your follow-up. The medication is paid to Eli Lilly at its self-pay price through LillyDirect®, which ships the pen to you. VevaMD does not charge you for the medication, and the full schedule is in the price section above.

  1. Complete the intake. A physician licensed in your state reviews your history, including any sleep apnea diagnosis.
  2. If Zepbound® is right for you, the prescription goes to LillyDirect®.
  3. Set up your LillyDirect® account and pay Eli Lilly there; keep refills on time, because Lilly’s self-pay price for the higher strengths depends on refilling within 45 days.
  4. Your physician manages each step-up and the check-ins after it, for the same membership price.

Who Zepbound is for

Approved for

  • Adults with obesity, or with overweight and at least one weight-related condition such as high blood pressure, high cholesterol or sleep apnea [1]
  • Adults with obesity and moderate to severe obstructive sleep apnea, whether or not they use a CPAP machine [1]

Not for

  • Anyone with a personal or family history of medullary thyroid carcinoma (MTC), or with MEN 2 [1]
  • Anyone with a serious allergy to tirzepatide [1]
  • Anyone who is pregnant; Zepbound is stopped when a pregnancy is recognized [1]
  • Anyone taking Mounjaro® or another GLP-1 medicine [1]

What the trials found

Weight. SURMOUNT-1 assigned 2,539 adults with obesity or overweight, without diabetes, to one of three maintenance strengths of tirzepatide or to placebo for 72 weeks. Average weight change was -15.0%, -19.5% and -20.9% on the three strengths and -3.1% on placebo, and at the two higher strengths half or more lost at least 20% of their weight, against 3% on placebo. Every cardiometabolic measure the trial set out to track improved on tirzepatide [4]. Participants averaged 38 in BMI at the start, and most were women [1].

Head to head. In SURMOUNT-5, 751 adults with obesity took tirzepatide or semaglutide, each at the highest dose they tolerated, for 72 weeks. Weight fell by an average of 20.2% on tirzepatide and 13.7% on semaglutide, and waist size by 18.4 cm against 13.0 cm [5].

Sleep apnea. The approval rests on two 52-week studies of 469 adults with obesity and moderate to severe sleep apnea, one in people using CPAP and one in people unable or unwilling to use it [2]. In the trial of people not using CPAP, breathing interruptions during sleep fell by about 25 events an hour on Zepbound against about 5 on placebo after 52 weeks, and 42% reached remission or mild apnea without daytime sleepiness, against 16% on placebo [1].

What to expect over time

  1. The first monthEveryone starts on the lowest strength for 4 weeks, so the body can get used to the medicine [1].
  2. Months 2 to 5Step-ups at least 4 weeks apart until your physician and you settle on a maintenance strength [1]. Nausea and other stomach effects mostly show up during these step-ups [4].
  3. Months 6 to 18In SURMOUNT-4, people who stayed on tirzepatide after 36 weeks lost a further 5.5% over the next year, for a total of 25.3% from the start [6].
  4. If you stopThose switched to placebo in SURMOUNT-4 regained 14.0% of their weight within a year [6]. Zepbound is a long-term treatment, and your physician plans any change with you.

Side effects and the boxed warning

Most common side effects in the Zepbound® weight trials (percent of people, highest strength)
Side effectZepbound®Placebo
Nausea28% [1]8%
Diarrhea23% [1]8%
Vomiting13% [1]2%
Constipation11% [1]5%
Stomach pain10% [1]5%
Injection-site reactions8% [1]2%

In SURMOUNT-1, side effects led 4.3% to 7.1% of people on tirzepatide to stop, against 2.6% on placebo [4]. The label’s serious risks include severe stomach side effects, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar with insulin or a sulfonylurea, diabetic eye complications, and aspiration during anesthesia [1].

Staying with it. Zepbound® treats a chronic disease. The Obesity Medicine Association notes that stopping a medicine like it carries a high risk of weight regain [7], and NIDDK points to at least 150 minutes a week of moderate activity to help keep weight off [3]. The Endocrine Society’s guideline treats these medicines as adjuncts to lifestyle change [8], which is how your physician builds the plan.

Zepbound compared with the other options

Your physician can recommend any of the four from one intake. Compounded tirzepatide is prepared by a pharmacy and is not FDA-approved or Zepbound®; Wegovy® is the FDA-approved semaglutide brand, as a pen or a pill.

The four GLP-1 options at VevaMD
FDA statusHow it is takenHow you pay at VevaMDMain trade-offs
Compounded semaglutideCompounded, not FDA-approvedWeekly injection from a vial, with vitamin B12One monthly price, as low as $199/mo: physician, medication and shipping. No membership feeThe lowest monthly price, the same at every dose; you draw each dose with a syringe
Compounded tirzepatideCompounded, not FDA-approvedWeekly injection from a vial, with vitamin B12One monthly price, as low as $299/mo: physician, medication and shipping. No membership feeActs on two gut-hormone receptors, GLP-1 and GIP; the same price at every dose; you draw each dose with a syringe
Wegovy®FDA-approved brandWeekly prefilled pen, or a daily tabletA $149/mo VevaMD membership, plus the self-pay price paid to Novo Nordisk ($348–$498/mo in total for the pen)Approved for weight and to lower heart risk in adults with heart disease; pen or pill; two separate charges
Zepbound®FDA-approved brandWeekly prefilled penA $149/mo VevaMD membership, plus the self-pay price paid to Eli Lilly ($448–$598/mo in total)Approved for weight and for moderate to severe sleep apnea with obesity; prefilled pen; two separate charges

Weight gain in perimenopause and menopause

Women in the menopause transition often find that the same habits no longer hold their weight. In SWAN, a long-running study of midlife women, fat gain sped up to twice its earlier rate as the transition began and lean mass started to decline [9]. Lower estrogen also shifts fat to the abdomen, and hot flashes and poor sleep get in the way of the routines that help [10].

Common questions

Is Zepbound approved for sleep apnea?

Yes. In December 2024 the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and more physical activity. It is the first medicine approved for that use.

Do I pay VevaMD for Zepbound itself?

No. VevaMD charges a membership for your physician and follow-up care. You pay Eli Lilly directly for Zepbound through LillyDirect, at Lilly’s self-pay price.

Why does refilling Zepbound on time matter?

Eli Lilly lists its lower self-pay prices for the higher Zepbound strengths when you refill within 45 days of your last delivery, and a higher regular price if the refill is later. Your VevaMD membership price does not change either way.

Is Zepbound the same medicine as Mounjaro?

Both are tirzepatide from Eli Lilly. Zepbound is approved for chronic weight management and sleep apnea; Mounjaro is approved for type 2 diabetes. The label advises against using them together.

What happens if I stop Zepbound?

In SURMOUNT-4, people switched from tirzepatide to placebo regained much of the weight they had lost within a year. Talk with your VevaMD physician before stopping so the change can be planned.

Does Zepbound help sleep apnea if I already use CPAP?

In the trial of people who kept using CPAP, breathing interruptions during sleep fell by about 29 an hour on Zepbound, against about 5 on placebo, after 52 weeks. Your physician reviews your sleep apnea history as part of the intake.

Can I switch from Wegovy to Zepbound?

Your VevaMD physician can review a switch through the same membership. The membership price stays the same; the medication is then paid to Eli Lilly instead of Novo Nordisk.

A physician decides what fits you

See if Zepbound fits me →

One private online intake covers every GLP-1 option. You see your price before you pay, and your first payment is refunded in full if nothing is prescribed.

Sources

  1. ZEPBOUND® (tirzepatide) injection prescribing information. Eli Lilly. DailyMed, revised September 2026. Checked October 28, 2026.
  2. FDA. FDA approves first medication for obstructive sleep apnea. News release, December 20, 2024. Checked October 28, 2026.
  3. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription medications to treat overweight and obesity. Checked October 28, 2026.
  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. Checked October 28, 2026.
  5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. Checked October 28, 2026.
  6. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. Checked October 28, 2026.
  7. Obesity Medicine Association. Weight loss medication side effects: know before you start. January 20, 2024. Checked October 28, 2026.
  8. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. Checked October 28, 2026.
  9. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. Checked October 28, 2026.
  10. The Menopause Society. MenoNote: Midlife weight gain. Checked October 28, 2026.

Last updated . Content standards

Clinical care is provided by board-certified, US-licensed physicians. VevaMD Inc is a technology and marketing storefront only — not a medical provider or a pharmacy. Medications are dispensed by licensed U.S. partner pharmacies after a valid prescription. Wegovy®, Ozempic®, Zepbound® and Mounjaro® are trademarks of their owners. VevaMD is not affiliated with Novo Nordisk or Eli Lilly. This page is general information, not medical advice. A prescription is not guaranteed, and outcomes differ from person to person. Report a side effect to FDA MedWatch.